Sarepta Therapeutics (SRPT) Cash & Equivalents (2010 - 2026)

Sarepta Therapeutics' Cash & Equivalents history runs 17 years deep, the most recent figure standing at $496.3 million for Q1 2026.

• In Q1 2026, Cash & Equivalents rose 106.04% year-over-year to $496.3 million; the TTM figure through Mar 2026 stood at $496.3 million (up 106.04% YoY), while the FY2025 annual figure was $714.6 million, down 35.21% from the prior year.
• Cash & Equivalents was $496.3 million for Q1 2026 at Sarepta Therapeutics, down from $714.6 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $1.2 billion in Q1 2022 to a low of $197.9 million in Q3 2024.
• Historically, Cash & Equivalents has averaged $663.6 million across 5 years, with a median of $541.9 million in 2023.
• Biggest YoY gain for Cash & Equivalents was 157.45% in 2024; the steepest drop was 63.49% in 2024.
• A 5-year view of Cash & Equivalents shows it stood at $966.8 million in 2022, then plunged by 55.68% to $428.4 million in 2023, then jumped by 157.45% to $1.1 billion in 2024, then plunged by 35.21% to $714.6 million in 2025, then plunged by 30.55% to $496.3 million in 2026.
• The last three Cash & Equivalents figures came in at $496.3 million (Q1 2026), $714.6 million (Q4 2025), and $404.6 million (Q3 2025), per Business Quant data.